A. Goran Ando's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 41,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 41,500 | 41,500 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Purchase of securities on an exchange or from another person at price $ 7.95 per share. | 21 Aug 2024 | 5,000 | 13,150 (0%) | 0% | 8.0 | 39,750 | Common Stock |
| EyePoint Pharmaceuticals Inc | A. Goran Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 23,598 | 23,598 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 27,100 | 27,100 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,500 | 13,500 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,250 | 8,150 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,250 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,250 | 3,250 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,750 | 4,900 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,750 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,750 | 2,750 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,150 | 2,150 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Goran A. Ando | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,150 | 0 | - | - | Restricted Stock Units |